Plerixafor

普乐沙福

Report date: 2026/02/24 20:00:16
NMEFirst In Class

Base Information

Drug NamePlerixafor
Drug Alias Nameplerixaforum释倍灵MozobilMobozilSDZ-SID-791 +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionC-X-C motif chemokine receptor 4 antagonists
TargetsC-X-C motif chemokine receptor 4
Therapy Area/IndicationsBone metastasesRejection of organ transplantationCoronavirus Disease 2019 (COVID-19) +[35] 
Global Approved IndicationsMultiple MyelomaLymphoma, Non-HodgkinLymphoma +[4] 
Approved Indications in ChinaMultiple MyelomaLymphoma, Non-Hodgkin
Original Approved Country/TerritoryUnited States
Original Approved Date2008/12/15
Country/TerritoryCzechiaBelgiumBulgaria +[20] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGenzyme Corp
China Registration ClassN/A

Develop Information

Active CompaniesSanofiHospital Israelita Albert EinsteinGenzyme Europe Bv +[5] 
Inactive CompaniesWeill Medical College of Cornell University4Living BiotechWashington University School Of Medicine +[12] 
Active IndicationsLymphopeniaNeutropeniaAgranulocytosis +[10] 
Inactive IndicationsBone metastasesRejection of organ transplantationCoronavirus Disease 2019 (COVID-19) +[25] 

Other Information

ATC CodeL03AX16
Related LinksWikipediaDrugBankKEGG